Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
Tech leads Asia share rally, gold near record high on Fed rate cut bets
2/10/2025
Oil rebounds from 16-week lows on prospects of tighter Russian crude sanctions
2/10/2025
US markets regulators start shuttering as government shutdown cuts federal funding
1er/10/2025
Central Asia's maiden crypto fund launched in Kazakhstan
1er/10/2025
Infra.Market files IPO papers via confidential route ; seeks to raise up to Rs 5,500-cr
1er/10/2025
Realtor Runwal Developers approaches Sebi to mobilise Rs 2,000 cr via IPO
1er/10/2025
